Protagenic Therapeutics Files Q1 2025 10-Q
Ticker: PTIXW · Form: 10-Q · Filed: May 13, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Protagenic Therapeutics filed its Q1 2025 10-Q, showing financial data for common stock, preferred stock, and warrants.
AI Summary
Protagenic Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Atrinsic, Inc., is incorporated in Delaware and headquartered in New York. The filing covers the first quarter of 2025 and includes financial data related to common stock, preferred stock, and warrants.
Why It Matters
This filing provides investors with the latest financial snapshot of Protagenic Therapeutics, Inc., detailing their financial position and performance for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can be complex and may indicate potential risks or opportunities for investors.
Key Numbers
- 10-Q — Form Type (Quarterly report filed with the SEC)
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported)
- 20250513 — Filing Date (Date the report was submitted to the SEC)
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 10-Q
- Atrinsic, Inc. (company) — Former name of Protagenic Therapeutics, Inc.
- NEW YORK (location) — Headquarters city
- DE (location) — State of incorporation
- 20250331 (date) — End of reporting period
FAQ
What is the primary purpose of this 10-Q filing?
This 10-Q filing provides a quarterly update on Protagenic Therapeutics, Inc.'s financial condition and results of operations for the period ending March 31, 2025.
What were the former names of Protagenic Therapeutics, Inc.?
Protagenic Therapeutics, Inc. was formerly known as Atrinsic, Inc., NEW MOTION, INC., and MPLC, Inc.
What is the company's state of incorporation and fiscal year end?
The company is incorporated in Delaware (DE) and its fiscal year ends on December 31.
What financial instruments are specifically mentioned in relation to the reporting period?
The filing mentions financial data related to us-gaap:CommonStockMember, PTIX:CommonStockPurchaseWarrantMember, and us-gaap:PreferredStockMember, including SeriesBConvertiblePreferredStockMember.
Where is Protagenic Therapeutics, Inc. headquartered?
Protagenic Therapeutics, Inc. is headquartered in New York (NY).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Protagenic Therapeutics, Inc.\new (PTIXW).